HISUN(SH:600267)2020-04-29 16:00Financial Performance - Operating revenue for the first quarter was ¥2,499,333,008.14, a decrease of 10.66% year-on-year[11] - Net profit attributable to shareholders was -¥71,410,895.85, representing a decline of 325.05% compared to the same period last year[11] - Basic earnings per share were -¥0.074, a decrease of 324.24% compared to the previous year[11] - The company reported a net profit margin of 16.2% for the quarter, reflecting a stable performance compared to the previous year[34] - Net profit for Q1 2020 was ¥51,070,646.08, a significant decline from ¥155,145,162.40 in Q1 2019, indicating a decrease of approximately 67%[51] - The net profit for Q1 2020 was a loss of ¥35,228,319.74, compared to a loss of ¥11,453,031.24 in Q1 2019, indicating a significant increase in losses[57] - The total comprehensive income for Q1 2020 was -¥38,322,472.67, compared to -¥11,453,031.24 in Q1 2019[59] Cash Flow - The net cash flow from operating activities increased significantly to ¥523,830,656.25, up 431.17% year-on-year[11] - The net cash flow from financing activities increased by 498.61% to ¥114,226,191.53, primarily due to new loans obtained during the quarter[22] - The net cash flow from operating activities for Q1 2020 was ¥523,830,656.25, a significant increase from ¥98,619,183.86 in Q1 2019[59] - The net cash flow from investing activities was -60,157,473.81, a decrease from -362,840,679.86 year-over-year[61] - The net cash flow from financing activities increased to 114,226,191.53 from -28,656,415.34 year-over-year[61] - The cash inflow from financing activities totaled 2,122,682,500.00, compared to 2,066,676,049.78 in the previous year[61] Assets and Liabilities - Total assets at the end of the reporting period reached ¥21,718,947,038.98, an increase of 1.18% compared to the end of the previous year[11] - Current assets totaled RMB 8,101,548,903.82, an increase of 5.4% from RMB 7,684,306,821.61 in the previous year[36] - Total liabilities reached RMB 14,142,207,016.98, an increase of 2.6% from RMB 13,783,024,398.47[39] - Current liabilities increased to ¥6,146,028,460.46 in Q1 2020, compared to ¥4,755,580,324.49 in Q1 2019, representing an increase of approximately 29.2%[47] - Long-term borrowings rose to ¥50,173,185.88 from ¥41,030,791.99, reflecting an increase of about 22.5%[47] - The company's total equity reached approximately 6.34 billion, with paid-in capital at about 965.53 million and capital reserves at approximately 3.72 billion[82] Shareholder Information - The total number of shareholders at the end of the reporting period was 120,708[19] - Zhejiang Haizheng Group Co., Ltd. held 33.22% of the shares, making it the largest shareholder[19] Investments and Acquisitions - The company completed the transfer of 20.24% equity in Zhejiang Daoming Pharmaceutical for ¥141.68 million, with the transfer registration completed on January 8, 2020[25] - The company increased its investment in Zhejiang Haizheng Sulikang Biotechnology Co., Ltd. by ¥6,693.07 million in fixed assets and ¥778 million in cash, raising its ownership to 91%[26] - The company acquired 49% equity in Zhejiang Haizheng Investment Management Co., Ltd. for ¥849,100, resulting in full ownership[28] - The company publicly listed the transfer of 33.33% equity in Zhejiang Jiayou Medical Devices Co., Ltd. with a base price of ¥25 million, which was successfully transferred on April 15, 2020[31] Research and Development - Research and development expenses increased to RMB 618,250,163.26, up 3.5% from RMB 599,170,960.62, indicating a focus on innovation[36] - Research and development expenses for Q1 2020 amounted to ¥75,089,062.71, compared to ¥88,846,467.86 in Q1 2019, showing a decrease of about 15.5%[51] - Research and development expenses for Q1 2020 were ¥41,253,988.74, slightly down from ¥43,350,487.63 in Q1 2019[57] Other Financial Metrics - The company reported non-recurring gains and losses totaling ¥13,923,887.42 for the quarter[14] - The company experienced increased depreciation and interest expenses, impacting net profit for the quarter[11] - The company reported an investment loss of ¥1,287,297.00 in Q1 2020, contrasting with a gain of ¥5,809,180.35 in Q1 2019[51] - The company experienced a credit impairment loss of ¥16,912,741.86 in Q1 2020, compared to a gain of ¥2,748,971.88 in Q1 2019[57]